Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Non-Current Liabilities of $119.2 billion for Q1 2026, up 1.74% sequentially from $117.2 billion in Q4 2025, and up 4.28% YoY from $114.3 billion in Q1 2025.
Johnson & Johnson (JNJ) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Total Non-Current Liabilities data on file, last reported at $119.2 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities rose 4.28% year-over-year to $119.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.2 billion (up 4.28% YoY) and the FY2025 annual result came in at $117.2 billion, up 9.11% from the prior year.
- Total Non-Current Liabilities rose to $119.2 billion in Q1 2026 per JNJ's latest filing, from $117.2 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $124.0 billion in Q2 2023, with the low at $93.7 billion in Q4 2023.
- Average Total Non-Current Liabilities over 5 years is $107.4 billion, with a median of $107.2 billion recorded in 2024.
- Year-over-year, Total Non-Current Liabilities climbed 20.16% in 2023 and fell 18.66% in 2024.
- Johnson & Johnson's Total Non-Current Liabilities stood at $100.0 billion in 2022, then dropped by 2.31% to $97.7 billion in 2023, then gained by 9.93% to $107.4 billion in 2024, then increased by 9.11% to $117.2 billion in 2025, then increased by 1.74% to $119.2 billion in 2026.
- Business Quant data shows JNJ's Total Non-Current Liabilities at $119.2 billion in Q1 2026, $117.2 billion in Q4 2025, and $103.6 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 48.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.22 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 109.01 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -34.06 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 75.17 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 80.55 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 31.56 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 113.51 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 10.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 119.22 Bn |
| Dec 28, 2025 | 117.18 Bn |
| Sep 28, 2025 | 103.61 Bn |
| Jun 29, 2025 | 104.65 Bn |
| Mar 30, 2025 | 114.33 Bn |
| Dec 29, 2024 | 107.40 Bn |
| Sep 29, 2024 | 106.91 Bn |
| Jun 30, 2024 | 108.30 Bn |
| Mar 31, 2024 | 100.83 Bn |
| Dec 31, 2023 | 97.69 Bn |
| Oct 1, 2023 | 93.66 Bn |
| Jul 2, 2023 | 114.14 Bn |
| Apr 2, 2023 | 123.96 Bn |
| Jan 1, 2023 | 109.45 Bn |
| Oct 2, 2022 | 100.00 Bn |
| Jul 3, 2022 | 100.83 Bn |
| Apr 3, 2022 | 103.16 Bn |
| Jan 2, 2022 | 107.46 Bn |
| Oct 3, 2021 | 108.34 Bn |
| Jul 4, 2021 | 106.27 Bn |